Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab.
Smith
David I
DI
Heffernan
Michael P
MP
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D014820:Vitiligo / Q000150:complications*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab